Skip to main content

Currently Skimming:

Appendix F Rescheduling Criteria
Pages 256-258

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 256...
... There must be adequate pharmacological and toxicological studies done by all methods reasonably applicable on the basis of which it could be fairly and responsibly concluded, by experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, that the substance is safe for treating a specific, recognized disorder.
From page 257...
... In the absence of NDA approval, information concerning the chemistry, pharmacology, toxicology, and effectiveness of the substance must be reported, published, or otherwise widely available in sufficient detail to permit experts, qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, to fairly and responsibly conclude the substance is safe and effective for use in treating a specific, recognized disorder.
From page 258...
... Schuster, Wayne State University 12:45 LUNCH :45 Marijuana and Glaucoma Paul Kaufman, University of Wisconsin 2:15 Effects of Marijuana and Cannabinoids in Neurological Disorders Paul Consroe, University of Arizona Health Sciences Center 2:45 Neural Mechanisms of Cannabinoid Analgesia Howard Fields, University of California at San Francisco 3:15 3:45 Pain Management Michael Rowbotham, University of California at San Francisco Wasting Syndrome Pathogenesis and Clinical Markers Donald Kotler, St. Lukes'-Roosevelt Hospital 4: 15 Clinical Experience with Marijuana Stephen O'Brien, East Bay AIDS Center 4:45 ADJOURN


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.